



February 3, 2024

To  
The Corporate Relations Department  
BSE Limited  
Phiroz Jeejeebhoy Towers, 25th Floor,  
Dalal Street,  
Mumbai- 400001  
**Scrip Code** - 543308  
**ISIN: INE967H01017**

To  
The Listing Department  
National Stock Exchange of India Limited  
Exchange Plaza,  
Bandra Kurla Complex, Bandra (East),  
Mumbai - 400 051  
**Symbol** - KIMS  
**ISIN: INE967H01017**

Dear Sir/Madam,

**Sub: Outcome of Board Meeting held on 3<sup>rd</sup> February 2024 pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.**

Further to our intimations dated 23<sup>rd</sup> January 2024, the Board of Directors, at its meeting held today has approved the unaudited (Standalone and Consolidated) financial results of the Company for the 3<sup>rd</sup> quarter and 9 (Nine) months ended 31<sup>st</sup> December 2023 together with Limited Review Reports which has been reviewed by the Audit Committee and approved by the Board of Directors.

The financial results are also available on the website of the Company at [https://www.kimshospitals.com/investors/Disclosures under Regulation 46 of SEBI \(LODR\) Regulations,2015/ Financial Information/ Financial Result](https://www.kimshospitals.com/investors/Disclosures_under_Regulation_46_of_SEBI_(LODR)_Regulations,2015/_Financial_Information/_Financial_Result) and on the websites of BSE Ltd and National Stock Exchange of India Ltd viz. [www.bseindia.com](http://www.bseindia.com) and [www.nseindia.com](http://www.nseindia.com), respectively.

Further, the financial results will also be published in the newspaper as per the requirement and in the format prescribed under SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015.

**Board Meeting Commenced at** : 2.00 P.M.

**Board Meeting Concluded at** : 5.15 P.M

This is for your information and records.

Thanking you,

**For Krishna Institute of Medical Sciences Limited**

**MANTHA**  
**SHANKER UMA**  
**Umashankar Mantha**  
**Company Secretary & Compliance Officer**  
Enclosed: As above

Digitally signed by MANTHA  
SHANKER UMA  
Date: 2024.02.03 17:21:32 +05'30'

**Krishna Institute of Medical Sciences Limited**

D.No.: 1-8-31/1, Minister Road, Secunderabad - 500 003, Telangana, India  
Phone: +91 40 4488 5000/4488 5184 | Fax: +91-40-27840980 | [kimshospitals.com](http://kimshospitals.com)  
CIN: L55101TG1973PLC040558


**Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Standalone Financial Results of Krishna Institute of Medical Sciences Limited Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended****Review Report to  
The Board of Directors  
Krishna Institute of Medical Sciences Limited**

1. We have reviewed the accompanying statement of unaudited standalone financial results of Krishna Institute of Medical Sciences Limited (the "Company") for the quarter ended December 31, 2023 and year to date from April 01, 2023 to December 31, 2023 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. The Company's Management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Statement has been approved by the Company's Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

**For S.R. BATLIBOI & ASSOCIATES LLP**

Chartered Accountants

ICAI Firm registration number: 101049W/E300004



per Navneet Rai Kabra

Partner

Membership No.: 102328

UDIN: 24102328BKZK08516


Hyderabad

February 03, 2024



Statement of Unaudited Standalone Financial Results for the quarter and nine months period ended 31 December 2023


		Quarter Ended			Nine months period ended		Year ended
		31-Dec-23 (Unaudited)	30-Sep-23 (Unaudited)	31-Dec-22 (Unaudited)	31-Dec-23 (Unaudited)	31-Dec-22 (Unaudited)	31-Mar-23 (Audited)
1	<b>Income</b>						
	(a) Revenue from operations	3,020.63	3,162.45	2,835.13	9,172.08	8,386.71	11,320.23
	(b) Other income	42.27	35.68	71.84	116.34	185.25	234.97
	<b>Total Income</b>	<b>3,062.90</b>	<b>3,198.13</b>	<b>2,906.97</b>	<b>9,288.42</b>	<b>8,571.96</b>	<b>11,555.20</b>
2	<b>Expenses</b>						
	(a) Purchase of medical consumables, drugs and surgical instruments	612.85	671.95	602.98	1,941.35	1,733.74	2,308.19
	(b) Decrease/(increase) in inventories of medical consumables, drugs and surgical instruments	12.60	(10.96)	(2.84)	(41.57)	55.74	67.43
	(c) Employee benefits expense	541.50	558.62	450.27	1,634.55	1,396.14	1,872.52
	(d) Other expenses	978.89	959.90	885.01	2,856.58	2,641.52	3,469.26
	(e) Finance cost	12.15	0.50	2.44	13.47	9.76	11.52
	(f) Depreciation and amortisation expense	127.84	127.93	113.48	377.01	341.38	452.95
	<b>Total Expenses</b>	<b>2,285.83</b>	<b>2,307.94</b>	<b>2,051.34</b>	<b>6,781.39</b>	<b>6,178.28</b>	<b>8,181.87</b>
3	<b>Profit before tax (1-2)</b>	<b>777.07</b>	<b>890.19</b>	<b>855.63</b>	<b>2,507.03</b>	<b>2,393.68</b>	<b>3,373.33</b>
4	<b>Tax expense</b>						
	(a) Current tax	192.47	233.41	198.51	637.20	609.14	837.62
	(b) Deferred tax charge/(credit)	1.05	(4.81)	12.45	(1.64)	6.63	10.82
	<b>Total tax expenses</b>	<b>193.52</b>	<b>228.60</b>	<b>210.96</b>	<b>635.56</b>	<b>615.77</b>	<b>848.44</b>
5	<b>Profit for the period/year (3-4)</b>	<b>583.55</b>	<b>661.59</b>	<b>644.67</b>	<b>1,871.47</b>	<b>1,777.91</b>	<b>2,524.89</b>
6	<b>Other comprehensive income</b>						
	Items that will not be reclassified subsequently to statement of profit and loss						
	- Re-measurement gain on defined benefit plans	2.61	2.46	3.07	7.82	9.22	11.00
	- Income tax effect	(0.66)	(0.62)	(0.77)	(1.97)	(2.32)	(2.77)
	<b>Other comprehensive income, net of tax</b>	<b>1.95</b>	<b>1.84</b>	<b>2.30</b>	<b>5.85</b>	<b>6.90</b>	<b>8.23</b>
7	<b>Total comprehensive income (5+6)</b>	<b>585.50</b>	<b>663.43</b>	<b>646.97</b>	<b>1,877.32</b>	<b>1,784.81</b>	<b>2,533.12</b>
8	<b>Paid up equity share capital (face value of Rs.10 each)</b>						
9	<b>Other Equity</b>						800.28
10	<b>Earnings per share (of Rs.10 each) : (not annualised for the quarter/period ended)</b>						15,508.31
	(a) Basic (Rs.)	7.29	8.27	8.06	23.39	22.22	31.55
	(b) Diluted (Rs.)	7.29	8.27	8.06	23.39	22.22	31.55



/ /

**Notes:**

- 1 In terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) 2015, this Statement of Unaudited Standalone Financial Results for the quarter and nine months period ended 31 December 2023 ("Unaudited Standalone Financial Results") of the Company has been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 03 February 2024 and have been subject to limited review by the statutory auditors of the Company. An unqualified report was issued by them thereon.
- 2 The Unaudited Standalone Financial Results of the Company have been prepared in accordance with the Indian Accounting Standards notified under Section 133 of the Companies Act 2013, as amended, read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) 2015, as amended (the "Listing requirements").
- 3 The Company operates in one single reportable business segment- "Medical and Healthcare services".
- 4 The above Unaudited Standalone Financial Results of the Company are available on the Company's website [www.kimshospitals.com](http://www.kimshospitals.com) and also on the website of BSE ([www.bseindia.com](http://www.bseindia.com)) and NSE ([www.nseindia.com](http://www.nseindia.com)), where the shares of the Company are listed.



For and on behalf of the Board  
Krishna Institute of Medical Sciences Limited

  
Dr. B Bhaskara Rao  
Managing Director

DIN: 00008985

Hyderabad  
03 February 2024



**Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Consolidated Financial Results of Krishna Institute of Medical Sciences Limited Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended**


**Review Report to  
The Board of Directors  
Krishna Institute of Medical Sciences Limited**

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of Krishna Institute of Medical Sciences Limited (the "Holding Company"), its subsidiaries (the Holding Company and its subsidiaries together referred to as "the Group"), and its associate for the quarter ended December 31, 2023 and year to date from April 01, 2023 to December 31, 2023 (the "Statement") attached herewith, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. The Holding Company's Management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Statement has been approved by the Holding Company's Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the Circular No. CIR/CFD/CMD1/44/2019 dated March 29, 2019 issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable.

4. The Statement includes the results of the following entities:

S.no.	Entity	Relationship
1	Krishna Institute of Medical Sciences Limited	Holding Company
2	Arunodaya Hospitals Private Limited	Subsidiary
3	KIMS Hospital Enterprises Private Limited	Subsidiary
4	Iconkrishi Institute of Medical Sciences Private Limited	Subsidiary
5	Saveera Institute of Medical Sciences Private Limited	Subsidiary
6	KIMS Hospital Kurnool Private Limited	Subsidiary
7	KIMS Hospitals Private Limited	Subsidiary
8	KIMS Swastha Private Limited	Subsidiary
9	KIMS Hospital (Bengaluru) Private Limited	Subsidiary
10	Sarvejana Healthcare Private Limited	Subsidiary



# S.R. BATLIBOI & ASSOCIATES LLP

Chartered Accountants

S.no.	Entity	Relationship
11	Rajyalakshmi Healthcare Private Limited	Subsidiary
12	Spanv Medisearch Lifesciences Private Limited	Subsidiary
13	KIMS Manavata Hospitals Private Limited	Subsidiary
14	Kondapur Healthcare Limited (Formerly known as RVM Healthcare Limited)*	Associate

\*Became an associate during the current period

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.
6. The accompanying Statement includes the unaudited interim financial results and other financial information, in respect of:
- Two subsidiaries, whose unaudited interim financial results include, total revenues of Rs Nil and Rs Nil, total net loss after tax of Rs. 1.14 million and Rs. 2.62 million, total comprehensive loss of Rs. 1.14 million and Rs. 2.62 million, for the quarter ended December 31, 2023 and for the period from April 01, 2023 to December 31, 2023 respectively, as considered in the Statement which have been reviewed by their respective independent auditors.
  - An associate, whose unaudited interim financial results include Group's share of net loss of Rs. 1.23 million and Rs. 1.45 million and Group's share of total comprehensive loss of Rs. 1.23 million and Rs. 1.45 million for the quarter ended December 31, 2023 and for the period from April 01, 2023 to December 31, 2023 respectively, as considered in the Statement whose interim financial results and other financial information have been reviewed by their respective independent auditors.

The independent auditor's reports on interim financial results of these entities have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures in respect of these subsidiaries and associate is based solely on the report of such auditors and procedures performed by us as stated in paragraph 3 above.

Our conclusion on the Statement in respect of matters stated in para 6 above is not modified with respect to our reliance on the work done and the reports of the other auditors.

**For S.R. BATLIBOI & ASSOCIATES LLP**

Chartered Accountants

ICAI Firm registration number: 101049W/E300004

*Navneet Rai*

per Navneet Rai Kabra

Partner

Membership No.: 102328

UDIN: 24102328BKEZKD2119

Hyderabad

February 03, 2024



Statement of Unaudited Consolidated Financial Results for the Quarter and Nine months period ended 31 December 2023

(Rupees in millions)

	Quarter ended						Nine months period ended		Year ended
	31-Dec-23	30-Sep-23	31-Dec-22	31-Dec-23	31-Dec-22	31-Mar-23			
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)		
<b>1 Income</b>									
(a) Revenue from operations	6,058.36	6,524.82	5,621.62	18,643.47	16,217.49		21,976.78		
(b) Other income	32.55	28.82	64.51	92.49	209.89		258.72		
<b>Total Income</b>	<b>6,090.91</b>	<b>6,553.64</b>	<b>5,686.13</b>	<b>18,735.96</b>	<b>16,427.38</b>		<b>22,235.50</b>		
<b>2 Expenses</b>									
(a) Purchase of medical consumables, drugs and surgical instruments	1,244.50	1,425.32	1,240.58	4,016.98	3,552.14		4,744.87		
(b) (Increase)/decrease in inventories of medical consumables, drugs and surgical instruments	11.17	(21.29)	(5.49)	(57.27)	33.55		61.60		
(c) Employee benefits expense	1,042.51	1,056.73	871.95	3,138.31	2,546.64		3,464.36		
(d) Other expenses	2,288.97	2,291.34	2,002.76	6,730.89	5,677.39		7,665.84		
(e) Finance cost	124.27	89.10	115.24	306.69	251.30		305.45		
(f) Depreciation and amortisation expense	353.76	326.07	332.92	1,002.48	938.29		1,292.60		
<b>Total Expenses</b>	<b>5,065.18</b>	<b>5,167.27</b>	<b>4,557.96</b>	<b>15,138.08</b>	<b>12,999.31</b>		<b>17,534.72</b>		
<b>3 Profit before share of loss from associate (1-2)</b>	<b>1,025.73</b>	<b>1,386.37</b>	<b>1,128.17</b>	<b>3,597.88</b>	<b>3,428.07</b>		<b>4,700.78</b>		
<b>4 Share of loss from associate, net of tax</b>	(1.23)	(0.22)	-	(1.45)	-		-		
<b>5 Profit before tax and exceptional items (3+4)</b>	<b>1,024.50</b>	<b>1,386.15</b>	<b>1,128.17</b>	<b>3,596.43</b>	<b>3,428.07</b>		<b>4,700.78</b>		
<b>6 Exceptional Items</b>	-	-	-	-	148.29		148.29		
<b>7 Profit before tax (5+6)</b>	<b>1,024.50</b>	<b>1,386.15</b>	<b>1,128.17</b>	<b>3,596.43</b>	<b>3,576.36</b>		<b>4,849.07</b>		
<b>8 Tax expense</b>									
(a) Current tax	218.53	362.69	290.03	900.14	895.43		1,183.91		
(b) Deferred tax	40.46	1.67	25.73	42.29	33.94		24.84		
(c) Adjustment of tax relating to earlier periods/years	-	8.85	(5.86)	8.85	(24.39)		(17.81)		
<b>Total tax expenses (8)</b>	<b>258.99</b>	<b>373.21</b>	<b>309.90</b>	<b>951.28</b>	<b>904.98</b>		<b>1,190.94</b>		
<b>9 Profit for the period/year (7-8)</b>	<b>765.51</b>	<b>1,012.94</b>	<b>818.27</b>	<b>2,645.15</b>	<b>2,671.38</b>		<b>3,658.13</b>		
<b>Attributable to:</b>									
Owners of the company	718.44	920.16	759.80	2,446.74	2,430.50		3,363.22		
Non controlling interests	47.07	92.78	58.47	198.41	240.88		294.91		
<b>10 Other comprehensive income for the period/year</b>									
Items that will not be reclassified subsequently to statement of profit and loss									
- Re-measurement gain on defined benefit plans	3.08	2.50	1.78	7.97	7.61		11.63		
- Income tax effect	(0.78)	(0.64)	(0.57)	(2.02)	(1.96)		(3.12)		
<b>Other comprehensive income, net of tax</b>	<b>2.30</b>	<b>1.86</b>	<b>1.21</b>	<b>5.95</b>	<b>5.65</b>		<b>8.51</b>		
<b>Attributable to:</b>									
Owners of the company	2.09	1.68	1.58	5.60	5.76		8.03		
Non controlling interests	0.21	0.18	(0.37)	0.35	(0.11)		0.48		
<b>11 Total comprehensive income (9+10)</b>									
Owners of the company	720.53	921.84	761.38	2,452.34	2,436.26		3,371.25		
Non controlling interests	47.28	92.96	58.10	198.76	240.77		295.39		
<b>Total comprehensive income</b>	<b>767.81</b>	<b>1,014.80</b>	<b>819.48</b>	<b>2,651.10</b>	<b>2,677.03</b>		<b>3,666.64</b>		
<b>12 Paid up equity share capital (face value of Rs.10 each)</b>							800.28		
<b>13 Other Equity</b>							15,895.10		
<b>14 Earnings per share (of Rs.10 each): (not annualised for the quarter/period ended)</b>									
(a) Basic (Rs.)	8.98	11.50	9.49	30.57	30.37		42.03		
(b) Diluted (Rs.)	8.98	11.50	9.49	30.57	30.37		42.03		



Notes:

- 1 In terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) 2015, this Statement of Unaudited Consolidated Financial Results for the quarter and nine months period ended 31 December 2023 ("Unaudited Consolidated Financial Results") of Krishna Institute of Medical Sciences Limited (the "Holding Company" or the "Company") its subsidiaries (the Holding Company and its subsidiaries together referred to as the "Group") and its associate has been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 03 February 2024 and have been subject to limited review by the statutory auditors of the Company. An unqualified report was issued by them thereon
- 2 The Unaudited Consolidated Financial Results of the Group have been prepared in accordance with the Indian Accounting Standards notified under Section 133 of the Companies Act 2013, as amended, read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) 2015, as amended (the "Listing requirements").
- 3 The Company operates in one single reportable business segment- "Medical and Healthcare services".
- 4 During the current quarter, group has acquired additional stake of 18.30% in its subsidiary SPANV Medisearch Lifesciences Private Limited and 8.39% in its associate Kondapur Healthcare Limited (Formerly known as RVM Healthcare Limited)
- 5 The above Unaudited Consolidated Financial Results of the Group are available on the Company's website [www.kimshospitals.com](http://www.kimshospitals.com) and also on the website of BSE ([www.bseindia.com](http://www.bseindia.com)) and NSE ([www.nseindia.com](http://www.nseindia.com)), where the shares of the Company are listed.

Hyderabad  
03 February 2024



For and on behalf of the Board  
Krishna Institute of Medical Sciences Limited

  
Dr. B. Bhaskara Rao  
Managing Director  
DIN: 00008985

